山东百龙创园生物科技股份有限公司2025年三季度业绩快报公告

Core Viewpoint - The company reported significant growth in both revenue and net profit for the third quarter of 2025, indicating a strong operational performance and effective product strategy [1][2]. Financial Performance - The total operating revenue for Q3 2025 reached 968.90 million yuan, representing an 18.10% year-on-year increase [1]. - The net profit attributable to shareholders was 264.63 million yuan, showing a substantial growth of 44.93% compared to the previous year [1]. - Basic earnings per share increased to 0.63 yuan, reflecting a 10.53% rise year-on-year [1]. Operational Highlights - The growth in revenue and profit was primarily driven by the optimization of the product structure and the release of production capacity from new projects, including a 30,000-ton soluble dietary fiber project and a 15,000-ton crystallized sugar project [1]. - The company's total assets amounted to 2.58 billion yuan, with a 28.03% increase from the beginning of the period [2]. - Shareholder equity reached 1.88 billion yuan, marking an 11.81% increase [2]. Shareholder Information - The total share capital increased to 420.01 million shares, a 30.00% rise due to a capital reserve distribution where every 10 shares were converted into 3 additional shares [2]. - The net asset value per share decreased to 4.47 yuan, down 13.99% from the beginning of the period, attributed to the increase in total share capital [2].